
|Articles|August 11, 2008
Cystoid macular oedema drug begins testing
IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















